- Reviews (0)
|Antigen/Gene or Protein Targets||Epidermal Growth Factor Receptor|
|Synonyms||EGFR, ErbB-1, HER1|
Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung, anal cancers, glioblastoma and epithelial tumors of the head and neck. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers.
Monoclonal 225 is a classic reagent in tumor therapy with more than 100 published references. The human/mouse chimeric antibody known as Cetuximab was derived from this monoclonal antibody.
Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.Review this reagent